Driven by Clinical Business, Cepheid's Q3 Revenues Rise 24 Percent | GenomeWeb
NEW YORK (GenomeWeb News) – Cepheid’s third-quarter revenues grew 24 percent, and the firm posted a 36 percent rise in net loss in the three-month period ended Sept. 30.
 
The Sunnyvale, Calif.-based molecular diagnostics firm brought in revenues of $44.9 million for the quarter compared to $36.3 million in the comparable quarter of 2007.
 
System product sales decreased 12 percent to $14 million from $15.9 million, while reagent and disposables sales jumped by 57 percent to $28.4 million from $18.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.